Medicines for Malaria Venture

Recent papers from Medicines for Malaria Venture

1. Discovery of a Pyrazine-2-Carboxamide Derivative as a Potent Plasmodium falciparum Inhibitor with Potential for Single-Dose CureJournal of Medicinal Chemistry · 2026
2. Evaluation of two delivery strategies to improve coverage and adherence to Seasonal Malaria Chemoprevention (SMC) in MaliMalaria Journal · 2026
3. Association between number of previous malaria episodes and treatment failure among children and adults with laboratory-confirmed Plasmodium infection treated with pyronaridine-artesunate in Gabon: a retrospective cohort studyMalaria Journal · 2026
4. The Governance Gap: Democratizing Drug Development Through Decision ArchitectureClinical Pharmacology & Therapeutics · 2026
5. Activated Platelets Express GPI-Anchored Fibrocystin-L (PKHD1L1), from Granules, Absent or Deficient in Paroxysmal Nocturnal HemoglobinuriaInternational Journal of Molecular Sciences · 2026
6. Early-stage anthelmintic discovery: Integrating phenotype, target and mechanismBiotechnology Advances · 2026
7. ICH E21: from landmark guidance to specific action for maternal and child healthJournal of Translational Medicine · 2026
8. Repurposing screens reveal a role for PKCη and NF1 in SARS-CoV-2 infectionPLoS Pathogens · 2026
9. Antimalarial cytoskeletal targeting with broad apicomplexan activityProceedings of the National Academy of Sciences · 2026
10. Health-care provider compliance with a revised Plasmodium vivax radical cure algorithm incorporating tafenoquine and quantitative G6PD testing in the Peruvian Amazon: a prospective observational studyThe Lancet Regional Health - Americas · 2026
11. Defining safety parameters for first-trimester malaria treatment trials: stakeholder views from Real-Time Delphi surveyMalaria Journal · 2026
12. 2-Amino-3,4-Dihydroquinazolines Exhibit Potent Antimalarial Activity by Targeting Plasmepsin XACS Infectious Diseases · 2026
13. New Malaria Prevention Modalities: Long-Acting Interventions Beyond VaccinesCold Spring Harbor Perspectives in Medicine · 2026
14. Prevalence of antimalarial drug resistance markers and factors associated with Plasmodium falciparum infection in asymptomatic children prior to rectal artesunate implementation in Kapolowe Health District, Democratic Republic of the CongoMalaria Journal · 2026
15. Safety, pharmacokinetics, and antimalarial efficacy of single-dose cabamiquine–pyronaridine combination therapy for the treatment of adults and adolescents with acute uncomplicated Plasmodium falciparum malaria (CAPTURE 1): a prospective, multicentre, open-label, phase 2a studyThe Lancet Infectious Diseases · 2026
16. Point of care performance of the improved BIOCREDIT Ag Pf/Pv (pLDH/pLDH) rapid diagnostic test: a cross-sectional study at a health center setting in EthiopiaMalaria Journal · 2026
17. Effects of malaria intermittent preventive treatment with dihydroartemisinin-piperaquine on antiretroviral drug concentrations in African pregnant women living with HIVAntimicrobial Agents and Chemotherapy · 2026
18. High-dose, short-course primaquine after point-of-care G6PD testing for the radical cure of Plasmodium vivax malaria: a safety study in Papua New Guinea and IndonesiaThe Lancet Regional Health - Western Pacific · 2026
19. The pyrrolidinamide antimalarial drug MMV367 rapidly clears blood-stage Plasmodium falciparum in healthy adults with experimental malariaScience Translational Medicine · 2026
20. Nonclinical Considerations for Support of Pregnancy and Lactation in Clinical TrialsBirth Defects Research · 2026